Quanterix Corporation (QTRX): Price and Financial Metrics
QTRX Price/Volume Stats
| Current price | $25.94 | 52-week high | $28.77 |
| Prev. close | $25.01 | 52-week low | $8.02 |
| Day low | $25.14 | Volume | 474,500 |
| Day high | $26.90 | Avg. volume | 341,851 |
| 50-day MA | $24.81 | Dividend yield | N/A |
| 200-day MA | $17.86 | Market Cap | 974.12M |
QTRX Stock Price Chart Interactive Chart >
QTRX POWR Grades
- QTRX scores best on the Growth dimension, with a Growth rank ahead of 96.69% of US stocks.
- QTRX's strongest trending metric is Growth; it's been moving up over the last 177 days.
- QTRX's current lowest rank is in the Momentum metric (where it is better than 12.19% of US stocks).
QTRX Stock Summary
- QTRX's price/sales ratio is 8.39; that's higher than the P/S ratio of 88.34% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.2 for QUANTERIX CORP; that's greater than it is for only 13.47% of US stocks.
- In terms of volatility of its share price, QTRX is more volatile than 86.03% of stocks we're observing.
- Stocks that are quantitatively similar to QTRX, based on their financial statements, market capitalization, and price volatility, are VBIV, RVNC, OSS, XMTR, and SHCR.
- QTRX's SEC filings can be seen here. And to visit QUANTERIX CORP's official web site, go to www.quanterix.com.
QTRX Valuation Summary
- QTRX's EV/EBIT ratio is -8.9; this is 176.72% lower than that of the median Healthcare stock.
- Over the past 70 months, QTRX's price/sales ratio has gone down 7.
Below are key valuation metrics over time for QTRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| QTRX | 2023-09-22 | 8.4 | 2.6 | -14.3 | -8.9 |
| QTRX | 2023-09-21 | 8.4 | 2.6 | -14.3 | -8.9 |
| QTRX | 2023-09-20 | 8.6 | 2.7 | -14.6 | -9.2 |
| QTRX | 2023-09-19 | 8.7 | 2.7 | -14.8 | -9.4 |
| QTRX | 2023-09-18 | 8.7 | 2.7 | -14.8 | -9.4 |
| QTRX | 2023-09-15 | 8.6 | 2.7 | -14.7 | -9.2 |
QTRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- QTRX has a Quality Grade of D, ranking ahead of 13.4% of graded US stocks.
- QTRX's asset turnover comes in at 0.276 -- ranking 59th of 75 Measuring and Control Equipment stocks.
- 500 - Internal server error
The table below shows QTRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.276 | 0.603 | -0.474 |
| 2021-03-31 | 0.318 | 0.590 | -0.489 |
| 2020-12-31 | 0.398 | 0.558 | -0.511 |
| 2020-09-30 | 0.397 | 0.525 | -0.611 |
| 2020-06-30 | 0.352 | 0.434 | -1.038 |
| 2020-03-31 | 0.385 | 0.460 | -1.276 |
QTRX Price Target
For more insight on analysts targets of QTRX, see our QTRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $76.00 | Average Broker Recommendation | 1.42 (Moderate Buy) |
Quanterix Corporation (QTRX) Company Bio
Quanterix Corporation develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and SR-X system that supports the detection capability of approximately six biomarkers per test. The company’s products also comprise kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, assay development, and custom development services. Quanterix Corporation primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was founded in 2007 and is based in Lexington, Massachusetts.
Latest QTRX News From Around the Web
Below are the latest news stories about QUANTERIX CORP that investors may wish to consider to help them evaluate QTRX as an investment opportunity.
Here's Why Investors Should Buy Alcon (ALC) Stock Right NowInvestors continue to be optimistic about Alcon (ALC) on the impressive performance of its portfolio. |
Here's Why You Should Retain Insulet (PODD) Stock for NowInvestors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system. |
Here's Why You Should Invest in Edward Lifesciences (EW) NowInvestors continue to be optimistic about Edward Lifesciences (EW) on the strength of TAVR and a solid balance sheet. |
Here's Why You Should Retain Omnicell (OMCL) Stock NowInvestors are optimistic about Omnicell (OMCL), owing to the strong prospect of the advanced services portfolio. |
Why You Should Add Haemonetics (HAE) to Your Portfolio NowHaemonetics' (HAE) share price is likely to grow, backed by solid business performance across all its segments. |
QTRX Price Returns
| 1-mo | 4.60% |
| 3-mo | 14.32% |
| 6-mo | 139.08% |
| 1-year | 211.78% |
| 3-year | -20.84% |
| 5-year | 16.06% |
| YTD | 87.29% |
| 2022 | -67.33% |
| 2021 | -8.82% |
| 2020 | 96.78% |
| 2019 | 29.06% |
| 2018 | -14.72% |
Continue Researching QTRX
Want to see what other sources are saying about Quanterix Corp's financials and stock price? Try the links below:Quanterix Corp (QTRX) Stock Price | Nasdaq
Quanterix Corp (QTRX) Stock Quote, History and News - Yahoo Finance
Quanterix Corp (QTRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...